Get the Stockscreener App
73.77
1.68%
1.22
Pre-market:
73.99
0.22
+0.30%
Haemonetics Corp stock is traded at $73.77, with a volume of 632.69K.
It is up +1.68% in the last 24 hours and up +3.78% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$72.55
Open:
$72.76
24h Volume:
632.69K
Relative Volume:
1.14
Market Cap:
$3.54B
Revenue:
$1.36B
Net Income/Loss:
$123.81M
P/E Ratio:
30.61
EPS:
2.41
Net Cash Flow:
$20.35M
1W Performance:
-3.77%
1M Performance:
+3.78%
6M Performance:
-1.95%
1Y Performance:
-16.86%
1-Day Range:
$72.71
$74.34
1-Week Range:
$72.06
$76.83
52-Week Range:
$55.30
$94.98
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
73.77 | 3.68B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ABT
Abbott Laboratories
|
124.42 | 229.71B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.78 | 154.35B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
387.32 | 149.60B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.70 | 114.97B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.56 | 45.92B | 5.54B | 4.18B | 623.10M | 7.00 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
What drives Haemonetics Corporation stock priceTriple-digit return opportunities - jammulinksnews.com
Why Haemonetics Corporation stock attracts strong analyst attentionFree Expert Investment Advice - Newser
Is Haemonetics Corporation a good long term investmentHigh-margin investment plays - jammulinksnews.com
Haemonetics Corporation Stock Analysis and ForecastExceptional trading results - jammulinksnews.com
What analysts say about Haemonetics Corporation stockOutstanding capital growth - jammulinksnews.com
Nisa Investment Advisors LLC Has $50,000 Position in Haemonetics Corporation (NYSE:HAE) - Defense World
Is Haemonetics Corporation stock a growth or value playMulti Bagger Alerts - Newser
What makes Haemonetics Corporation stock price move sharplyBig Return Stock Tips - Newser
How Haemonetics Corporation stock performs during market volatilityHigh Win Rate Stock Ideas - Newser
Platelet Aggregation Devices Market Set to Witness Significant - openPR.com
Lantheus, ICU Medical, Haemonetics, CONMED, and Astrana Health Shares Plummet, What You Need To Know - Yahoo Finance
Haemonetics Announces Q1 FY26 Earnings Release and Conference Call - AInvest
Haemonetics Shares Rise After Upgrade From Citigroup - MarketScreener
Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes - Investing.com
Haemonetics (NYSE:HAE) Coverage Initiated by Analysts at Robert W. Baird - Defense World
Analyst Baird Initiates Coverage on Haemonetics (HAE) with Outperform Rating | HAE Stock News - GuruFocus
Vivasure submits PMA for vascular closure system to FDA - Yahoo Home
Private cloud, AI compute markets continue to gain momentum - SiliconANGLE
Kalkine: Haemonetics (NYSE:HAE) Reflects Unique Sector Metrics in the russell 1000 - Kalkine Media
Haemonetics at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Blood Platelets Market Deep Research Report with Forecast - openPR.com
Haemonetics at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com
Transcript : Haemonetics Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
Zacks Research Decreases Earnings Estimates for Haemonetics - Defense World
Q3 EPS Estimates for Haemonetics Decreased by Zacks Research - Defense World
Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 36%? - Yahoo Finance
Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference - Quantisnow
Haemonetics (HAE) – Investment Analysts’ Recent Ratings Updates - Defense World
Decoding Haemonetics Corp (HAE): A Strategic SWOT Insight - GuruFocus
HAEMONETICS CORP SEC 10-K Report - TradingView
JMP maintains Haemonetics stock $100 target post-results By Investing.com - Investing.com Canada
What 4 Analyst Ratings Have To Say About Haemonetics - Benzinga
Haemonetics (HAE) Stock Rating and Price Target Reaffirmed by JMP Securities | HAE Stock News - GuruFocus
JMP maintains Haemonetics stock $100 target post-results - Investing.com
Haemonetics Co. (NYSE:HAE) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Haemonetics Corporation (NYSE:HAE) Q4 2025 Earnings Call Transcript - Insider Monkey
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up - Yahoo Finance
Haemonetics’ (HAE) “Strong-Buy” Rating Reiterated at Raymond James - Defense World
Haemonetics Corporation Just Beat EPS By 8.7%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Haemonetics Full Year 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings - Yahoo Finance
Raymond James Reiterates Strong Buy on Haemonetics (HAE) with Lo - GuruFocus
Raymond James Reiterates Strong Buy on Haemonetics (HAE) with Lowered Price Target | HAE Stock News - GuruFocus
Raymond James Adjusts Haemonetics (HAE) Price Target to $105, Ma - GuruFocus
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.15%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):